NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 78 resultados LastUpdate Última actualización 11/08/2020 [14:25:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

NºPublicación: US2020246474A1 06/08/2020

Solicitante:

UNIV MICHIGAN REGENTS [US]

CA_3082077_A1

Resumen de: US2020246474A1

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

traducir

METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER

NºPublicación: WO2020159987A1 06/08/2020

Solicitante:

BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]

Resumen de: WO2020159987A1

Provided are methods for the treatment of cancers including leukemias, that utilize combination therapies. In some embodiments, a metal chelator is administered to a patient in combination with a cancer therapy, zinc, selenium, magnesium, and vitamin C to treat the cancer. In some embodiments, increased efficacy of the cancer therapy can be observed, and/or lower dosages of a chemotherapeutic may be administered to the subject as a result of the combination therapy.

traducir

METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN ACUTE MYELOID LEUKEMIA BY USING EXOSOME-DERIVED IMMUNOPHENOTYPE

NºPublicación: WO2020159181A1 06/08/2020

Solicitante:

UNIV KOREA RES & BUS FOUND [KR]
UNIV-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIV [KR]
KOREA ADVANCED INST SCI & TECH [KR]

Resumen de: WO2020159181A1

The present invention relates to a method for predicting the relapse of acute myeloid leukemia, the method comprising the steps of: 1) isolating exosomes from a sample collected from a patient confirmed to be completely cured of acute myeloid leukemia; and 2) measuring the expression levels of CD53 and CD47 in the exosomes.

traducir

ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF

NºPublicación: WO2020156439A1 06/08/2020

Solicitante:

TUOJIE BIOTECH (SHANGHAI) CO LTD [CN]

Resumen de: WO2020156439A1

The present invention relates to an anti-CD79B antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Furthermore, the present invention relates to a chimeric antibody and a humanized antibody comprising a CDR region of the anti-CD79B antibody, a pharmaceutical composition comprising the anti-CD79B antibody or the antigen-binding fragment thereof, and a use thereof as an anti-cancer drug. Particularly, the present invention relates to a humanized anti-CD79B antibody, and a use thereof in preparation of a drug for treating lymphoma (such as DLBCL).

traducir

USE OF STEM CELLS PRODUCED BY STEM CELL GENERATOR IN TREATMENT OF HEMATOPOIETIC DAMAGE

NºPublicación: WO2020156390A1 06/08/2020

Solicitante:

UNIV EAST CHINA SCIENCE & TECH [CN]

Resumen de: WO2020156390A1

Disclosed is a stem cell generator for the generation of organoids after the development of biological materials loaded with active substances which are implanted into an animal or a human body. The active substances are mesenchymal stem cells, bone morphogenetic protein-2 or bone morphogenesis protein-7, other growth factors/polypeptides or growth factors/polypeptide combinations having the ability of inducing bone regeneration, or combinations thereof. The stem cell generator contains various types of blood cells and hematopoietic progenitor/stem cells having complete functions. The produced stem cells are used for treating hematopoietic damage, and can treat bone marrow failure and leukemia caused by radiotherapy/chemotherapy.

traducir

PHARMACEUTICAL COMPOSITION DERIVED FROM TECOMA PLANT AND A METHOD FOR TREATING CANCER

NºPublicación: US2020247786A1 06/08/2020

Solicitante:

NAT GUARD HEALTH AFFAIRS [SA]
KING SAUD BIN ABDULAZIZ UNIV FOR HEALTH SCIENCES [SA]
KING ABDULLAH INTERNATIONAL MEDICAL RES CENTER [SA]

Resumen de: US2020247786A1

A pharmaceutical composition containing an anti-proliferative compound, named Tecomaphorbide, which is identified and isolated from Tecoma plants (e.g. Tecoma stans). The pharmaceutical composition may contain a derivative and/or a salt of Tecomaphorbide. A process of obtaining Tecomaphorbide from Tecoma plants is specified. A method of treating cancer (e.g. leukemia, lymphoma, breast, colon, and prostate cancer) with the pharmaceutical composition is also provided.

traducir

COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR

NºPublicación: WO2020157709A1 06/08/2020

Solicitante:

PFIZER INC [US]

Resumen de: WO2020157709A1

This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.

traducir

METHODS OF TREATING MULTIPLE MYELOMA

NºPublicación: WO2020160020A1 06/08/2020

Solicitante:

SANOFI SA [FR]
CAMPANA ZAMBRANO FRANK [US]

Resumen de: WO2020160020A1

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.

traducir

INDIRUBIN DERIVATIVES, AND USES THEREOF

NºPublicación: US2020247750A1 06/08/2020

Solicitante:

HOPE CITY [US]
THE NATIONAL AND KAPODISTRIAN UNIV OF ATHENS [GR]

US_2014275168_A1

Resumen de: US2020247750A1

Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.

traducir

BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY

NºPublicación: WO2020160537A1 06/08/2020

Solicitante:

UNIV SOUTH CAROLINA [US]
SENEX BIOTECHNOLOGY INC [US]

Resumen de: WO2020160537A1

Disclosed herein are bicyclic pyridines, such as thienopyridine, pyrrolopyridine, furopyridine compounds, and methods for treating cancers. The method may comprise administering a therapeutically effective amount of any of the compositions described herein. In some embodiments, the cancer is a prostate cancer, a leukemia, a breast cancer, colon cancer, ovarian cancer, pancreatic cancer, or melanoma.

traducir

ICARIIN DERIVATIVES FOR USE IN TREATING MYELODYSPLASIA SYNDROME

NºPublicación: EP3689420A1 05/08/2020

Solicitante:

H LEE MOFFITT CANCER CENTER & RES INSTITUTE INC [US]

AU_2019204363_A1

Resumen de: EP3689420A1

Disclosed are compounds of Formula II, III-A, V-A or VI-A, as defined herein, for use in treating myelodysplastic syndrome.

traducir

METHOD FOR DIAGNOSING LYMPHOMA VIA BACTERIAL METAGENOMIC ANALYSIS

NºPublicación: EP3690065A1 05/08/2020

Solicitante:

MD HEALTHCARE INC [KR]

Resumen de: EP3690065A1

The present invention relates to a method of diagnosing lymphoma by bacterial metagenomic analysis, and more particularly, to a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples. The extracellular vesicles secreted from bacteria present in the environment are absorbed into the body to have a direct influence on the development of cancer cells, and since it is difficult to diagnose lymphoma early before symptoms are shown, effective treatment is difficult. Therefore, by previously predicting the risk of the onset of lymphoma through metagenomic analysis of bacterial extracellular vesicles using a human-derived sample according to the present invention, a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.

traducir

NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA

NºPublicación: EP3687537A1 05/08/2020

Solicitante:

DANA FARBER CANCER INST INC [US]

Resumen de: WO2019067503A1

The present disclosure relates to inhibitors of USP7 useful in the treatment of and other USP7 mediated diseases, having the Formula: wherein R1, R2, R3, R4, R5, R 6, and n are described herein.

traducir

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

NºPublicación: EP3689383A1 05/08/2020

Solicitante:

US HEALTH [US]

JP_2020078322_A

Resumen de: EP3689383A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

METHOD OF USING ANTI-CD79B IMMUNOCONJUGATES

NºPublicación: EP3689910A2 05/08/2020

Solicitante:

HOFFMANN LA ROCHE [CH]

US_2019201382_A1

Resumen de: EP3689910A2

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

traducir

SPECIFIC T CELL RECEPTORS AGAINST EPITOPES OF MUTANT MYD88L265P PROTEIN FOR ADOPTIVE T CELL THERAPY

NºPublicación: WO2020152161A1 30/07/2020

Solicitante:

UNIV BERLIN CHARITE [DE]

Resumen de: WO2020152161A1

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a MYD88 L265P peptide of SEQ ID NO: 2 in the context of HLA-B*07:02 having a high avidity to said peptide/HLA complex. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, as well as the medical use of such nucleic acids, proteins or host cells, in particular, in the diagnosis, prevention and/or treatment of a MyD88 L265P expressing cancer such as a non-Hodgkin B-cell lymphoma selected from the group comprising diffuse large B-cell lymphoma (DLBCL), e.g., activated B-cell-like DLBCL (ABC-DLBCL) or pCNS DLBCL, cutaneous DLBCL, leg-type DLBCL or testicular DLBCL; lymphoplasmacytic lymphoma (LPL), e.g., Waldenstrom macroglobulinemia (WM); and IgM monoclonal gammopathy (IgM MGUS).

traducir

NON-HUMAN ANIMAL MODELS OF SÉZARY SYNDROME

NºPublicación: WO2020152331A1 30/07/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV DE PARIS [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]

Resumen de: WO2020152331A1

Sézary syndrome is a rare, aggressive, and leukemic form of cutaneous T-cell lymphoma (CTCL) characterized by erythroderma associated with generalized peripheral lymphadenopathy and circulating clonal malignant T cells called Sézary cells. Current animal models of Sézary syndrome are not satisfactory since no cutaneous symptoms or occurrence of metastases could be observed. Now the inventors developed a new non-human animal model that repeat the major cutaneous symptoms of the human disease. This model could be suitable for screening new drugs and biomarkers of the disease.

traducir

TREATMENT OF T CELL LYMPHOMA

NºPublicación: WO2020152081A1 30/07/2020

Solicitante:

INNATE PHARMA [FR]

Resumen de: WO2020152081A1

The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.

traducir

PYRROLOBENZODIAZEPINE DERIVATIVES AS INHIBITORS OF NF-KAPPA B FOR THE TREATMENT OF PROLIFERATIVE DISEASES

NºPublicación: WO2020152462A1 30/07/2020

Solicitante:

KING S COLLEGE LONDON [GB]

Resumen de: WO2020152462A1

The invention relates to a compound of formula (I) or salts, solvates, stereoisomers, tautomers or combinations thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; and R1 and R2 are either (i) R1 and R2 together form a double bond; (ii) R1 is H and R2 is OH; or (iii) R1 is H and R2 is OC1-6 alkyl; Y is N-RB, S or O; Y1 is N or C-R8; q is o or 1; Het is where the carbonyl of the Het group is attached to the Y- & Y1-containing heterocyclic ring; Y2 is N-RB, S or O; Y3 is N or C-R10; Y4 is N-RB, S or O; Y5 is N or C-R10; Rx is H, RB, (CH2)m-ORB, halo, (CH2)m-NHRB and CO2RB; and each RB is independently selected from H, C1-6 alkyl and C1-6 haloalkyl. The invention also describes pharmaceutical compositions, and kits comprising compounds of formula (I) and their use for treating proliferative diseases such as multiple myeloma or chronic lymphocytic leukaemia and as NF-κΒ inhibitors.

traducir

BISPECIFIC ANTI-CD28 X ANTI-CD22 ANTIBODIES AND USES THEREOF

NºPublicación: US2020239576A1 30/07/2020

Solicitante:

REGENERON PHARMA [US]

WO_2020132066_A1

Resumen de: US2020239576A1

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

traducir

CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS

NºPublicación: WO2020154531A1 30/07/2020

Solicitante:

MILLENNIUM PHARM INC [US]
MOLECULAR TEMPLATES INC [US]

Resumen de: WO2020154531A1

The instant invention provides binding proteins ("CD38-binding proteins") which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide ("Shiga toxin effector polypeptide"). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38- binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38- expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.

traducir

TRUNCATED GUINEA PIG L-ASPARAGINASE VARIANTS AND METHODS OF USE

NºPublicación: US2020239867A1 30/07/2020

Solicitante:

UNIV ILLINOIS [US]

CN_111050784_A

Resumen de: US2020239867A1

Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.

traducir

Anti-metalloprotease antibody for diagnosis and treatment of cancers

NºPublicación: AU2020205221A1 30/07/2020

Solicitante:

LUDWIG INST FOR CANCER RES LTD [US]
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
UNIV MONASH [AU]

US_2017008976_A1

Resumen de: AU2020205221A1

Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells That also express the putative tumour stem cell marker CD 133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight AD AMI 0 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

traducir

Activin-ActRIIa antagonists and uses for promoting bone growth in cancer patients

NºPublicación: AU2020204583A1 30/07/2020

Solicitante:

ACCELERON PHARMA INC [US]

AU_2018204248_A1

Resumen de: AU2020204583A1

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.

traducir

PROTEOLYSIS TARGETING CHIMERIC MOLECULE, PREPARATION METHOD, AND APPLICATION

Nº publicación: WO2020151229A1 30/07/2020

Solicitante:

UNIV CHINA PHARMA [CN]

CN_109761970_A

Resumen de: WO2020151229A1

Disclosed are a proteolysis targeting chimeric molecule, a preparation method, and an application. The provided proteolysis targeting chimeric molecule can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used for preparing a drug for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule when n = 3 has excellent photoisomerization activity, and can be used for prepare a reagent or drug for degrading BCR-ABL and/or CRBN protein by light regulation. Also provided is a method for synthesizing this series of proteolysis targeting chimeric molecules.

traducir

Página1 de 4 nextPage por página

punteroimgVolver